CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $13
CCORF has reiterated its Buy rating for Compass Therapeutics (CMPX.US) and maintained its target price at $13. This indicates continued confidence from the firm in the pharmaceutical company's stock performance.
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement
Compass Therapeutics (CMPX) has received strong analyst confidence, indicated by a "Strong Buy" rating from Noble Financial. This optimism is primarily driven by the advancements of its drug candidate CTX-10726. The drug has shown promising preclinical results in various cancer cell lines and as a combination therapy, leading to significant projections for its market potential.
CMPX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Compass Therapeutics Inc.'s (CMPX) financial performance, focusing on its revenue, profitability margins, and a comparison with competitors PCRX and CTMX. It highlights the company's N/A gross, operating, and net margins, and a Return on Equity of -41.29%. The analysis also benchmarks CMPX's market capitalization and gross margin against its peers.
Compass Therapeutics Inc. (CMPX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Compass Therapeutics Inc. (CMPX) stock. It shows the current stock price, recent performance, and indicates that there is no analyst rating or earnings information currently available for the company. The page also promotes a virtual trading conference and free trade alerts.
CMPX Forecast, Price Target & Analyst Ratings | COMPASS THERAPEUTICS INC (NASDAQ:CMPX)
The article provides a comprehensive analyst forecast for COMPASS THERAPEUTICS INC (CMPX), including a consensus price target of $13.77, indicating a potential 152.66% upside from its current price of $5.45. It details upcoming earnings estimates for Q1 2026, analyst rating history, and long-term growth forecasts for EPS, revenue, and EBIT, with a strong "Buy" consensus from 22 analysts.
Stifel reiterates Compass Therapeutics stock rating ahead of trial data
Stifel has reiterated a Buy rating and a $12.00 price target for Compass Therapeutics (NASDAQ:CMPX) as the company awaits critical Phase 3 trial data in April 2026. Despite a 168% return over the past year, InvestingPro suggests the stock may be slightly overvalued, with analyst targets varying significantly due to its high-risk, high-reward nature. The firm's analysis of a proxy trial for biliary tract cancer outcomes supports the potential for positive results from Compass's COMPANION-002 trial.
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from Guggenheim
Guggenheim has reaffirmed a "Buy" rating for Compass Therapeutics (NASDAQ:CMPX), setting a $12 price target that suggests a potential 140% upside. The company reported a Q4 loss of $0.09 per share, beating estimates by $0.01, and analysts expect a full-year EPS of -0.36. Despite trading down 0.9% on Tuesday, the stock maintains a consensus "Moderate Buy" rating among analysts with an average target price of $13.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average recommendation of "Moderate Buy" from fifteen brokerages, with several analysts initiating or reiterating buy/outperform ratings and an average 12-month price target of $13.00. Institutional investors and hedge funds have significantly increased their stakes in CMPX, demonstrating confidence in the clinical-stage biotechnology company focused on immuno-oncology therapies. Despite a negative price-to-earnings ratio, the company recently surpassed Q4 earnings per share estimates, with analysts expecting further improvements in the current year.
Compass Therapeutics Sees Major Institutional Investment Boost
Suvretta Capital Management LLC significantly increased its stake in Compass Therapeutics (NASDAQ:CMPX) by 97.2% in the third quarter of 2025, now owning approximately 10.2% of the company. This substantial institutional investment highlights growing investor confidence in the clinical-stage biotech company and its innovative cancer immunotherapies. The move suggests that sophisticated investors see strong potential in Compass Therapeutics' pipeline and strategy, which could help advance its therapies through clinical development.
Compass Therapeutics, Inc. $CMPX Stock Position Lifted by Suvretta Capital Management LLC
Suvretta Capital Management LLC significantly increased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 97.2% in the third quarter, now owning over 14.1 million shares valued at approximately $49.35 million, representing about 10.20% of the company. Other institutional investors also raised their positions, contributing to a high institutional ownership of 68.43%. Wall Street analysts generally maintain a "Moderate Buy" rating for CMPX, with a consensus price target of $13.00, while the stock recently opened at $5.19 and has a market cap of around $934.7 million.
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy?
Compass Therapeutics (CMPX) has filed a shelf registration to offer over 11 million shares, valued at US$62.23 million, for its employee stock ownership plans, following a US$66.49 million net loss in 2025. This move highlights the company's continued reliance on equity financing for R&D and an effort to align staff incentives with long-term outcomes. While this reinforces existing investment risks and catalysts rather than fundamentally shifting strategy, investors should note the implications of ongoing losses and potential dilution.
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026
Cantor Fitzgerald has reiterated an "Overweight" rating for Compass Therapeutics, Inc. (CMPX) on March 12, 2026, ahead of key clinical trial data readouts. The firm expressed confidence in the company's clinical progress but did not issue a new price target, leading to a modest 1.42% decline in CMPX stock. This rating underscores institutional endorsement and focuses attention on the upcoming clinical catalysts, particularly given CMPX's status as a catalyst-driven opportunity with limited analyst coverage.
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy?
Compass Therapeutics recently filed a shelf registration to offer up to $62.23 million in stock for employee ownership plans, following a significant 2025 net loss of $66.49 million. This move highlights the company's reliance on equity financing for R&D and aims to align employee incentives with long-term outcomes. While this reinforces existing risks of cash burn and dilution, it doesn't fundamentally change its investment narrative, which centers on clinical trial milestones rather than revenue.
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development
Compass Therapeutics, Inc. has publicly acknowledged and celebrated the significant contributions of women in driving innovation within science and therapy development. The company highlighted the crucial role of women in both research laboratories and clinical settings, emphasizing their leadership, skill, and dedication in advancing new therapies for patients. Compass Therapeutics expressed appreciation for these women who are instrumental in fulfilling the company's mission.
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com
Citizens has reaffirmed its Market Outperform rating and a $10.00 price target for Compass Therapeutics (NASDAQ:CMPX), citing the company's progress in clinical trials. The biotech firm recently reported fourth-quarter 2025 earnings and announced that its pivotal COMPANION-002 trial reached the required number of events for overall survival in Q1 2026, with a readout expected in April. Several other analysts, including Jefferies, William Blair, Raymond James, and Craig-Hallum, have also provided positive ratings or initiated coverage, highlighting the company's potential in cancer therapies and upcoming data readouts.
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its full 2025 financial results, highlighting significant progress with its lead asset, tovecimig, which met its primary endpoint in a Phase 2/3 study. The company also announced strong clinical activity for CTX-8371 and FDA clearance for CTX-10726, with a solid cash position of $209 million expected to fund operations into 2028. Key leadership promotions were also announced as the company looks towards a "defining year" in 2026.
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance
Compass Therapeutics (CMPX) is under valuation scrutiny following trial milestones and FDA clearance, contrasting with notable net losses for 2025. Despite recent share price declines, the company shows strong long-term momentum, trading at a premium price-to-book ratio compared to other US Biotechs. A discounted cash flow model suggests significant undervaluation, indicating that the market might be heavily pricing in trial risk.
What is HC Wainwright's Estimate for CMPX Q1 Earnings?
HC Wainwright analyst J. Pantginis projects Compass Therapeutics (CMPX) to report Q1 2026 EPS of ($0.09) and a full-year loss of ($0.36) per share. Compass Therapeutics recently reported Q1 EPS of ($0.09), surpassing the consensus estimate of ($0.10). The company currently holds a "Moderate Buy" rating with an average target price of $13.00, while its shares trade near $5.53.
Jefferies raises Compass Therapeutics stock price target on trial progress
Jefferies has increased its price target for Compass Therapeutics (NASDAQ:CMPX) to $9.00 from $8.00, maintaining a Buy rating due to the company's progress in its second-line bladder cancer Phase II/III trial. The trial has met its prespecified overall survival threshold, with key data expected in April. Several other analysts, including William Blair, Raymond James, Craig-Hallum, and Canaccord Genuity, also hold positive outlooks for CMPX, citing promising pipeline developments and upcoming data readouts.
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company is anticipating key secondary endpoint results for tovecimig in biliary tract cancer in April and has expanded enrollment for CTX-8371 in TNBC, NSCLC, and Hodgkin lymphoma. With $209 million in cash and marketable securities, Compass Therapeutics has a projected cash runway into 2028.
Cancer trial hits survival milestone as Compass funds work to 2028
Compass Therapeutics reported a net loss of $66.5 million in 2025 but maintains a strong cash position of $209 million, projected to fund operations until 2028. Key clinical milestones include tovecimig meeting its primary ORR endpoint in the COMPANION-002 study, with PFS/OS analyses expected in April 2026, and advancements in other pipeline candidates like CTX-8371 and CTX-10726. The company anticipates a defining year in 2026 with ongoing clinical trial progress and an expanded leadership team.
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics reported its full 2025 financial results and provided a business update, highlighting significant progress with its lead asset, tovecimig, and advancements in its other clinical-stage programs. The company expects to report key secondary endpoint results for tovecimig in April and has a strong financial position with $209 million in cash and marketable securities, providing a runway into 2028. Additionally, expansion cohorts for CTX-8371 are open for enrollment, and CTX-10726 received FDA clearance for its Phase 1 study.
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics has released its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company reported $209 million in cash and marketable securities, providing a runway into 2028. Key updates include reaching the event threshold for its tovecimig study in biliary tract cancer, expanding cohorts for CTX-8371 in TNBC and NSCLC, and FDA clearance for CTX-10726, with Phase 1 studies commencing.
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS
Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings, reporting a loss of ($0.09) per share, which surpassed the consensus estimate of ($0.10) per share by $0.01. Following the announcement, the stock traded up approximately 2.5% to $5.83. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $13.36, and institutional investors own 68.43% of the stock.
Compass Therapeutics' 2025 net loss widens as R&D costs jump
Compass Therapeutics' net loss for 2025 has increased due to a significant rise in research and development costs. The article, originating from Reuters, briefly notes the financial results for the company.
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss
Compass Therapeutics reported $0.0 million in licensing revenue and a net loss of $66.5 million, or $(0.42) per share, with an operating loss widening to $(72.8) million due to increased development costs. The company advanced several pipeline assets and secured significant equity offerings, projecting current cash and securities to fund operations and clinical programs into 2028. Management also initiated commercialization activities in anticipation of future product launches.
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss
Compass Therapeutics (CMPX) reported a Q4 net loss of $0.09 per share, matching the FactSet estimate. The company focuses on developing proprietary antibody-based therapeutics for various human diseases, with a pipeline including CTX-009, CTX-471, and CTX-8371. The stock closed at $5.510 on March 6, 2026.
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Palo Alto Investors LP has initiated a significant new position in Compass Therapeutics (CMPX), adding over 2.5 million shares valued at $13.6 million as of December 31, 2025. This transaction represents 1.89% of the fund's assets under management. Compass Therapeutics is a clinical-stage biotech company focused on developing antibody therapeutics for cancer and has seen its stock price increase over 100% in the past year.
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story
Palo Alto Investors LP initiated a new stake in Compass Therapeutics (CMPX) in late 2025, purchasing 2.53 million shares worth US$13.6 million. This investment, alongside the potential of Compass's bispecific antibody Tovecimig, signifies growing institutional confidence in its oncology pipeline, despite the company's current unprofitability and reliance on further capital raises. The article emphasizes that while this new stake doesn't alter Compass Therapeutics' fundamental financial challenges, it reinforces the willingness of some institutions to support its clinical narrative.
Monashee Investment Management Boosts Stake in Compass Therapeutics
Monashee Investment Management LLC significantly increased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 657.6% during the third quarter, now owning 1.25 million shares. This substantial investment suggests the hedge fund sees considerable upside potential in Compass Therapeutics' pipeline of novel immuno-oncology therapies. Monashee is now one of Compass Therapeutics' largest institutional investors, holding approximately 0.9% of the company's outstanding shares.
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX
Monashee Investment Management LLC significantly increased its stake in Compass Therapeutics (NASDAQ:CMPX) by 657.6% in the third quarter, bringing its total holding to 1,250,000 shares valued at approximately $4.38 million. This move makes Compass Therapeutics the firm's 17th largest holding, representing about 0.9% of its portfolio. Other institutional investors like Vanguard Group Inc., Vivo Capital LLC, and Adage Capital Partners GP L.L.C. also boosted their positions, with institutional investors now owning 68.43% of CMPX. Analysts currently have a "Moderate Buy" rating for the stock, with an average price target of $13.36, significantly higher than its current share price near $5.65.
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com
Compass Therapeutics is preparing to report its fourth-quarter and full-year 2025 results, with investor focus primarily on the progress of its lead cancer treatment, tovecimig, and its potential commercial launch. The biotech is expected to post a loss of $0.10 per share and no revenue, but analysts maintain a bullish outlook with a "Strong Buy" rating for the stock. Key areas of interest include pivotal survival data from the COMPANION-002 study, the company's cash position, and its commercial readiness preparations, including the recent appointment of a Chief Commercial Officer.
Compass Therapeutics Inc. expected to post a loss of 9 cents a share - Earnings Preview
Compass Therapeutics Inc. (CMPX) is projected to report a loss of 9 cents per share. This information comes from a Refinitiv earnings preview. The article provides a quick financial snapshot for the company.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $13.36 among firms that have issued reports. The company operates as a clinical-stage immuno-oncology biotechnology firm, focusing on developing novel therapies like CTX-471 and DSP107. Shares are currently trading around $6.17, with significant institutional investor interest, including increased stakes from Vivo Capital and Suvretta Capital Management.
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday
Compass Therapeutics (NASDAQ:CMPX) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, 2026. Analysts project a loss of ($0.10) per share for the quarter. The stock has a "Moderate Buy" consensus rating and an average price target of $13.36, with significant institutional investor activity observed in the fourth quarter.
Compass Therapeutics (NASDAQ:CMPX) Raised to "Hold" at Wall Street Zen
Wall Street Zen has upgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "hold" rating, contributing to an overall "Moderate Buy" consensus from analysts with a target price of $13.00. The company, a clinical-stage immuno-oncology firm, saw its stock open at $6.28, with a market cap of $1.12 billion, and institutional investors collectively own 68.43% of its shares. Several large investors, including Suvretta Capital Management LLC, Vivo Capital LLC, and Vanguard Group Inc., significantly increased their stakes in CMPX during the last quarter.
Craig-Hallum initiates coverage on Compass Therapeutics stock with Buy rating
Craig-Hallum has initiated coverage on Compass Therapeutics (NASDAQ:CMPX) with a "Buy" rating and a $15.00 price target. The firm is confident in the biotech company's approach to developing bispecific antibodies for cancer therapies, highlighting lead asset tovecimig and its potential near-term commercial opportunity. This positive outlook comes despite the stock's significant rally, with other analysts also maintaining bullish ratings and price targets.
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech With 109% Potential Upside
Compass Therapeutics, Inc. (CMPX) is presented as a promising biotechnology investment with a 109% potential upside, according to analyst targets. Despite being in the clinical-stage with current negative financial metrics typical for its sector, the company focuses on innovative antibody-based therapeutics for oncology. Strong analyst confidence, indicated by 15 buy ratings and no hold or sell ratings, along with an oversold RSI, suggests potential for significant future growth.
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Craig Hallum
Craig Hallum has initiated coverage on Compass Therapeutics (NASDAQ:CMPX) with a "buy" rating and a $15 price target, suggesting a 136.59% upside. This adds to a generally positive analyst outlook, with the company currently holding a "Moderate Buy" consensus rating and an average target price of $13.00. Institutional investors significantly own the stock, with recent stake increases from firms like Suvretta, Vivo, and Vanguard.
Compass Therapeutics stock rises after Craig-Hallum initiates coverage with Buy
Compass Therapeutics' stock increased by 3.1% after Craig-Hallum initiated coverage with a Buy rating and a $15.00 price target. The firm expressed confidence in the company's bispecific antibody approach for cancer therapies, highlighting its lead asset, tovecimig, and promising early-stage pipeline candidates. Despite an 84% rally over the past year, Craig-Hallum anticipates further upside as the company moves towards commercialization and its assets gain clinical validation.
Canaccord Genuity raises Compass Therapeutics stock price target on Phase 2/3 data expectations
Canaccord Genuity increased its price target for Compass Therapeutics (NASDAQ:CMPX) to $13.00 from $10.00, maintaining a Buy rating, based on anticipated positive Phase 2/3 data for their combination therapy. The firm cited a "low bar" for the therapy and manageable safety concerns. Compass Therapeutics is also making progress in its cancer drug pipeline with key survival analyses expected and notable leadership appointments.
Canaccord Genuity raises Compass Therapeutics stock price target on Phase 2/3 data expectations
Canaccord Genuity has increased its price target for Compass Therapeutics (NASDAQ:CMPX) from $10.00 to $13.00, maintaining a Buy rating on the stock. This adjustment is driven by anticipated positive Phase 2/3 data for tovecimig plus paclitaxel, expected by the end of Q1 2026. The firm notes a "low bar" for the combination therapy and manageable safety concerns, with several other analysts also holding positive ratings on the company.
Compass Therapeutics (NASDAQ:CMPX) Sets New 1-Year High - Here's What Happened
Compass Therapeutics (NASDAQ:CMPX) recently hit a new 52-week high, trading as high as $6.71 with significant intraday gains. This surge is supported by broadly positive analyst sentiment, with an average "Moderate Buy" rating and a price target of $12.23, along with substantial institutional accumulation. Hedge funds and other institutions now own approximately 68.43% of the stock, with several prominent firms increasing their stakes.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics (CMPX) stock reached a 52-week high of $6.51 USD, marking a nearly 99% surge over the past year. The biotech firm's market capitalization stands at $1.14 billion, with impressive returns over the last six months and year-to-date. Analysts maintain a bullish outlook, with price targets ranging from $8 to $30, supported by significant progress in its cancer drug pipeline and strategic leadership appointments.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics (CMPX) stock reached a new 52-week high of $6.51 USD, marking a significant 98.76% surge over the past year and a 116.95% return over six months. The biotech firm and its market capitalization of $1.14 billion is supported by a strong financial position, with analysts setting price targets between $8 and $30. The company also reported progress in its cancer drug pipeline, including upcoming survival analyses for tovecimig and a positive response for CTX-8371, alongside key executive appointments.
Compass Therapeutics stock hits 52-week high at 6.51 USD By Investing.com
Compass Therapeutics' stock (CMPX) has reached a new 52-week high of $6.51 USD, marking a significant surge of 98.76% over the past year. The company, with a market capitalization of $1.14 billion, has seen substantial growth due to strategic advancements and strong investor confidence. Analysts maintain bullish ratings, projecting further upside potential for the biotech firm.
Compass Therapeutics stock hits 52-week high at 6.51 USD
Compass Therapeutics' (CMPX) stock reached a 52-week high of $6.51 USD, reflecting a 98.76% surge over the past year and a market capitalization of $1.14 billion. The biotech firm's growth is supported by a strong financial position and analyst recommendations, with price targets ranging from $8 to $30. Recent advancements in its cancer drug pipeline and strategic leadership appointments further contribute to investor confidence.
Wall Street Zen Upgrades Compass Therapeutics (NASDAQ:CMPX) to "Hold"
Wall Street Zen has upgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "hold" rating, joining several other firms with "buy" or "outperform" coverage. The company, focused on immuno-oncology therapies, has a "Moderate Buy" consensus rating with a $12.23 target price from MarketBeat. Compass Therapeutics recently reported better-than-expected quarterly EPS and its stock opened at $6.40, with a 12-month trading range of $1.33–$6.49.
Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year High - Here's Why
Compass Therapeutics (NASDAQ:CMPX) recently hit a new 52-week high, trading as high as $6.48 and closing at $6.41, representing a 3.6% rise on significant volume. The company, which focuses on immuno-oncology therapies, has a "Moderate Buy" consensus rating from analysts, with an average price target of $12.23. Institutional investors have also been increasing their holdings in the stock.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Compass Therapeutics, Inc. (CMPX) has gained 20.2% recently, and Wall Street analysts project a potential upside of 113.7% with a mean price target of $13.23. Despite the skepticism often surrounding analyst price targets, a strong agreement on projected earnings improvements among analysts, coupled with a Zacks Rank #2 (Buy), suggests a legitimate upside for the stock. Investors are advised to consider price targets critically but acknowledge the positive trends in earnings estimate revisions.
